{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T09:52:53Z","timestamp":1761472373025,"version":"build-2065373602"},"reference-count":15,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T00:00:00Z","timestamp":1373328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rapid Comm Mass Spectrometry"],"published-print":{"date-parts":[[2013,8,30]]},"abstract":"\n RATIONALE<\/jats:title>\n \n Research on disorders of the central nervous system (CNS) has shown that an imbalance in the levels of specific endogenous neurotransmitters may underlie certain CNS diseases. These alterations in neurotransmitter levels may provide insight into pathophysiology, but can also serve as disease and pharmacodynamic biomarkers. To measure these potential biomarkers\n in vivo<\/jats:italic>\n , the relevant sample matrix is cerebrospinal fluid (CSF), which is in equilibrium with the brain's interstitial fluid and circulates through the ventricular system of the brain and spinal cord. Accurate analysis of these potential biomarkers can be challenging due to low CSF sample volume, low analyte levels, and potential interferences from other endogenous compounds.\n <\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n A protocol has been established for effective method development of bioanalytical assays for endogenous compounds in CSF. Database searches and standard\u2010addition experiments are employed to qualify sample preparation and specificity of the detection thus evaluating accuracy and precision.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n This protocol was applied to the study of the histaminergic neurotransmitter system and the analysis of histamine and its metabolite 1\u2010methylhistamine in rat CSF.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n The protocol resulted in a specific and sensitive novel method utilizing pre\u2010column derivatization ultra high performance liquid chromatography\/tandem mass spectrometry (UHPLC\/MS\/MS), which is also capable of separating an endogenous interfering compound, identified as taurine, from the analytes of interest. Copyright \u00a9 2013 John Wiley & Sons, Ltd.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/rcm.6639","type":"journal-article","created":{"date-parts":[[2013,7,15]],"date-time":"2013-07-15T22:13:26Z","timestamp":1373926406000},"page":"1882-1886","source":"Crossref","is-referenced-by-count":5,"title":["Addressing the need for biomarker liquid chromatography\/mass spectrometry assays: A protocol for effective method development for the bioanalysis of endogenous compounds in cerebrospinal fluid"],"prefix":"10.1002","volume":"27","author":[{"given":"Yulia","family":"Benitex","sequence":"first","affiliation":[{"name":"Molecular Sciences and Candidate Optimization, Bioanalytical Research Bristol\u2010Myers Squibb Company, Research & Development 5 Research Parkway Wallingford CT 06492 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen A.","family":"McNaney","sequence":"additional","affiliation":[{"name":"Molecular Sciences and Candidate Optimization, Discovery Analytical Sciences Bristol\u2010Myers Squibb Company, Research & Development 5 Research Parkway Wallingford CT 06492 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Luchetti","sequence":"additional","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Company, Research & Development 5 Research Parkway Wallingford CT 06492 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Schaeffer","sequence":"additional","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Company, Research & Development 5 Research Parkway Wallingford CT 06492 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy V.","family":"Olah","sequence":"additional","affiliation":[{"name":"Molecular Sciences and Candidate Optimization, Bioanalytical Research Bristol\u2010Myers Squibb Company, Research & Development Route 206 and Province Line Road Lawrenceville NJ 08543 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Molecular Sciences and Candidate Optimization, Bioanalytical Research Bristol\u2010Myers Squibb Company, Research & Development 5 Research Parkway Wallingford CT 06492 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter M.","family":"Drexler","sequence":"additional","affiliation":[{"name":"Molecular Sciences and Candidate Optimization, Discovery Analytical Sciences Bristol\u2010Myers Squibb Company, Research & Development 5 Research Parkway Wallingford CT 06492 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.07.038"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1139\/jpn.0919","article-title":"Glutamate and dopamine components in schizophrenia","volume":"34","author":"Seeman P.","year":"2009","journal-title":"J. Psychiatry Neurosci."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2013.v7.1.9"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1921"},{"key":"e_1_2_6_6_1","unstructured":"Available:www.hmdb.ca."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2010.00212.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(94)00034-6"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-100381"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1027"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.05.030"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-011-0379-5"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2010.09.045"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-011-5224-8"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac202794q"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac801339z"}],"container-title":["Rapid Communications in Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frcm.6639","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frcm.6639","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rcm.6639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T09:43:55Z","timestamp":1761471835000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/rcm.6639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,9]]},"references-count":15,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2013,8,30]]}},"alternative-id":["10.1002\/rcm.6639"],"URL":"https:\/\/doi.org\/10.1002\/rcm.6639","archive":["Portico"],"relation":{},"ISSN":["0951-4198","1097-0231"],"issn-type":[{"type":"print","value":"0951-4198"},{"type":"electronic","value":"1097-0231"}],"subject":[],"published":{"date-parts":[[2013,7,9]]}}}